Aldeyra Therapeutics (ALDX) Tops Q2 EPS by 3c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Aldeyra Therapeutics (NASDAQ: ALDX) reported Q2 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44).
For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Twitter's (TWTR) 'Underweight' Rating Reiterated at Morgan Stanley
- Rambus (RMBS) Tops Q3 EPS by 3c; Issues Q4 Outlook
- Knowles (KN) Tops Q3 EPS by 7c; Guides Q4
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!